{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-018410","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.341984+00:00","generated_at":"2026-06-08T07:13:08.446758+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"HOOKIPA reports Q3 2023 net loss of $19.1M; HB-200 shows 42% ORR in HPV16+ HNSCC","bullets":["Revenue of $6.9M, up from $2.2M YoY, mainly from Gilead and Roche collaboration recognition.","Net loss of $19.1M vs $18.3M YoY; R&D expenses increased to $24.6M from $18.3M.","Cash and equivalents $108.1M as of Sep 30, 2023, down from $113.4M at Dec 31, 2022.","HB-200 + pembro achieved 42% ORR in 19 evaluable CPI-naïve patients, doubling historical 19% for pembro alone.","Anticipated milestones: Phase 2 HB-200 data H1 2024, randomized trial mid-2024; IND filings for HB-700 (H1 2024) and HB-500 (Q4 2023)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-018410","json":"https://secwatch.observer/filing/0001558370-23-018410.json","markdown":"https://secwatch.observer/filing/0001558370-23-018410.md","text":"https://secwatch.observer/filing/0001558370-23-018410.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000155837023018410/0001558370-23-018410-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000155837023018410/hook-20231109x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:13:08.446758+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6fc72c46ac5082b43e3b8cfba24772d01434b85f","claim":"HOOKIPA Pharma Inc. reported third quarter of 2023 results: revenue $6.9 million, net income $19.1 million.","evidence_excerpt":"The decrease was primarily attributable to cash used in operating activities, partly offset by funds resulting from the follow-on financing in June 2023. ​ Revenue: Revenue was $6.9 million for the three months ended September 30, 2023 and $2.2 million for the three months ended September 30, 2022. This increase was primarily due to higher partial recognition of the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1760542/000155837023018410/0001558370-23-018410-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2023"},{"label":"Revenue","value":"$6.9 million"},{"label":"Net income","value":"$19.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}